Lobeglitazone

Summary

Lobeglitazone (CHEMBL3585580) is a phase-3 clinical-stage small molecule (ATC A10BG04); indicated across 2 conditions including diabetes mellitus and type 2 diabetes mellitus.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: A10BG04
• Indications: 2 conditions
• Clinical trials: 6
• Chemistry: 480.5 Da · C24H24N4O5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3585580
Name	Lobeglitazone
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9826451
ATC	A10BG04
Molecular formula	C24H24N4O5S
Molecular weight	480.5
InChIKey	CHHXEZSCHQVSRE-UHFFFAOYSA-N

SMILES: CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC(=NC=N3)OC4=CC=C(C=C4)OC

IUPAC name: 5-[[4-[2-[[6-(4-methoxyphenoxy)pyrimidin-4-yl]-methylamino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione

Also known as: Lobeglitazona, Lobeglitazone, lobeglitazone, LOBEGLITAZONE

Parent form; salt/anhydrous children: CHEMBL3780740

Patent coverage: 459 distinct patent families (1,212 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,012 (83%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Peroxisome proliferator-activated receptor gamma, Peroxisome proliferator-activated receptor alpha.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PPARG	8.52	EC50	3	nM	CHEMBL_ACT_25110714
PPARG	7.75	IC50	18	nM	CHEMBL_ACT_25110727

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
diabetes mellitus	2	MONDO:0005015	EFO:0000400
type 2 diabetes mellitus	1	MONDO:0005148	MONDO:0005148

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE4	4
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02285205	PHASE4	COMPLETED	A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD
NCT02315287	PHASE4	UNKNOWN	Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management
NCT02338921	PHASE4	COMPLETED	Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy
NCT05915949	PHASE4	UNKNOWN	Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety
NCT02002611	PHASE1	COMPLETED	Drug-drug Interaction Study(Lobeglitazone, Warfarin)
NCT02854748	PHASE1	UNKNOWN	Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).